CAS: 533884-09-2; (3As,4R,9Br)-4-(4-Hydroxyphenyl)-1,2,3,3A,4,9B-Hexahydrocyclopenta[c]Chromen-8-Ol
该化合物是一个复杂的有机化合物,其特征是其多环结构,包括一个环球(c)benzopyran mothy.这种化合物具有多个立体特征,有助于其风性,能够影响其生物活动和相互作用.在苯环上存在一个氢氧基化合物,表明氢联结的潜力和极溶剂中的溶性增加.此外,六氢结构表明,这是一种饱和化合物,可能影响其再活性和稳定性.这种化合物经常因其潜在的药用特性而研究,包括抗氧化剂和反氟虫活动,因此对药化学感兴趣.
- 英文名称(3As,4R,9Br)-4-(4-Hydroxyphenyl)-1,2,3,3A,4,9B-Hexahydrocyclopenta[c]Chromen-8-Ol
- 中文名称(3aS,4R,9bR)-1,2,3,3a,4,9b-六氢-4-(4-羟基苯基)环戊并[c][1]苯并吡喃-8-醇
- IUPAC名称Erteberel
- 其它别名(3As,4R,9Br)-4-(4-Hydroxyphenyl)-1,2,3,3A,4,9B-Hexahydrocyclopenta(C)(1)Benzopyran-8-Ol; Erteberel (Usan/inn); Erteberel [inn]; Erteberel [who-Dd]; Erteberel [usan:Inn]; (2R,6S,7R)-7-(4-
- CAS编号533884-09-2
- MFCD编号:MFCD22495234
- FDA UNII编号:2ZUL6758TZ
- 分子式:C18H18O3分子量:282.34
- 产品CID: 1518634
- 产品分类生物化工 → 抑制剂 → 内分泌及激素(Endocrinology & Hormones)
物理性质
MSDS等安全信息
上下游产品
2-(2,5-bis-methoxymethoxyphenyl)cyclopent-1-enecarboxylic acid methyl ester methyl 2-(trifluoromethylsulfonyloxy)cyclopent-1-enecarboxylate methyl 2-ox°Cyclopentane-1-carboxylate 8-(benzyloxy)-2,3-dihydr°Cyclopenta[c]chromen-4(1H)-one合成工艺路线路线简述
📜(4-(Benzyloxy)Phenyl)((1S,2R)-2-(2,5-Bis(Benzyloxy)Phenyl)Cyclopentyl)Methanone置于5%-Palladium/activated Carbon,氢气,原甲酸三乙酯,Lithium Bromide体系中,用 四氢呋喃,乙醇 作为反应溶剂,化学反应 6.0H,以90%的收率获得产物芬克罗酮
参考文献:铑催化和锌(II)-三叶草促进的四取代α,β-不饱和酮的不对称加氢反应
标题:铑催化和锌(II)-三叶草促进的四取代α,β-不饱和酮的不对称加氢反应
摘要:使用原位形成的铑-Josiphos催化剂已经完成了四取代的α,β-不饱和酮的不对称氢化.加入催化性三氟甲磺酸锌(II)可以增强反应,在抑制产物差向异构化的同时显着提高周转频率.
DOI:10.1021/ol203264A
海关参考信息
- 2902600000-乙苯
2902700000-异丙基苯
2905121000-正丙醇
2906210000-苄醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2024351965-A1
优先权日:2021-08-23
标 题 :Synthesis and Evaluation of Novel (4-Hydroxyphenyl) Substituted Carbocycles as Potent and Selective Estrogen Receptor Beta Agonists
发明人：DONALDSON WILLIAM A; SEM DANIEL S; WETZEL EDWARD A
权利人:UNIV MARQUETTE; CONCORDIA UNIV INC
摘要:Disclosed are 4-hydroxylphenyl substituted carbocycles and there use as selective agonists of the estrogen receptor beta isoform (ERβ). The disclosed compounds may be formulated as pharmaceutical compositions and administered to treat diseases associated with ER activity, such as proliferative diseases and disorders and/or psychiatric diseases or disorders.
专利号:WO-2023028074-A1
优先权日:2021-08-23
标 题 :Synthesis and evaluation of novel (4-hydroxyphenyl) substituted carbocycles as potent and selective estrogen receptor beta agonists
专利号:EP-4392487-A1
优先权日:2021-08-23
标题:Synthesis and evaluation of novel (4-hydroxyphenyl) substituted carbocycles as potent and selective estrogen receptor beta agonists
专利号:AU-2022332910-A1
优先权日:2021-08-23
标 题 :Synthesis and evaluation of novel (4-hydroxyphenyl) substituted carbocycles as potent and selective estrogen receptor beta agonists
专利号:CA-3229664-A1
优先权日:2021-08-23
标 题 :Synthesis and evaluation of novel (4-hydroxyphenyl) substituted carbocycles as potent and selective estrogen receptor beta agonists
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Wu W, Warner M, Wang L, He WW, Zhao R, Guan X, Botero C, Huang B, Ion C, Coombes C, Gustafsson JA. Drivers and suppressors of triple-negative breast cancer. Proc Natl Acad Sci U S A. 2021 Aug 17;118(33):e2104162118. doi: 10.1073/pnas.2104162118.
2: Karakas B, Aka Y, Giray A, Temel SG, Acikbas U, Basaga H, Gul O, Kutuk O. Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells. Cell Death Discov. 2021 Jul 22;7(1):189. doi: 10.1038/s41420-021-00573-2.
3: Sareddy GR, Pratap UP, Venkata PP, Zhou M, Alejo S, Viswanadhapalli S, Tekmal RR, Brenner AJ, Vadlamudi RK. Activation of estrogen receptor beta signaling reduces stemness of glioma stem cells. Stem Cells. 2021 May;39(5):536-550. doi: 10.1002/stem.3337. Epub 2021 Feb 1.
合成参考文献
摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
📝 需求与反馈
尽可能描述清楚需求与问题信息
